SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Battalion Oil Corp. engages in the acquisition, production, exploration, and development of liquids-rich oil and natural gas assets in the Delaware Basin. The company was founded in 1987 and is headquartered in Houston, TX.

Battalion Oil Corp - Ordinary Shares (New)

Battalion Oil Corp ($BATL) is experiencing a massive rally, fueled by reports of Iran threatening or closing the Strait of Hormuz, leading to anticipation of surging oil prices. The low-float energy stock is seeing intense community discussion around a potential short squeeze, driven by extremely high borrow fees and expectations of reaching $20-$50+.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is trending amid surging interest in photonics solutions for AI data centers, buoyed by recent institutional investment, a strategic partnership mention from Quantum Computing, and NVIDIA's broader sector validation. The community is actively discussing POET's optical interposer technology as a key enabler for next-generation high-speed interconnects and eagerly awaits major customer announcements.

MongoDB, Inc. engages in the development and provision of a general-purpose database platform. The firm's products include MongoDB Enterprise Advanced, MongoDB Atlas, and Community Server. It also offers professional services including consulting and training. The company was founded by Eliot Horowitz, Dwight A. Merriman, Kevin P. Ryan, and Geir Magnusson Jr. in November 2007 and is headquartered in New York, NY.

MongoDB Inc - Ordinary Shares - Class A

MongoDB Inc

MongoDB is trending following a significant stock drop, driven by cautious short-term guidance and recent leadership transitions, despite strong past earnings. This has ignited community debate, with some citing broader software sector pressures and growth concerns, while others see it as an exaggerated sell-off presenting a long-term buying opportunity given its AI and database platform.

Indonesia Energy Corp. Ltd. operates as an oil and gas, exploration, and production company. It engages in oil and gas assets portfolio with a mix between medium-sized producing blocks and exploration blocks with significant resources. Its portfolio includes Kruh, Citarum, and Rangkas Area. The company was founded by James J. Huang and Wirawan Jusuf in 2014 and is headquartered in Jakarta, Indonesia.

Indonesia Energy Corp Ltd

Indonesia Energy Corp is trending as escalating Middle East tensions, including Iran's threats regarding the Strait of Hormuz and attacks on oil infrastructure, fuel expectations for surging oil prices. The community is actively discussing INDO's potential for a significant upward move, drawing comparisons to other energy stocks that have already seen large gains, despite some frustration over its current price action.

Gorilla Technology Group, Inc. engages in the provision of video intelligence, Internet of Things (IoT) security, edge AI data analytics, and operational technology security solutions and services in Asia Pacific. It operates through the following segments: Video IoT, Security Convergence, and Other. The company was founded by Spincer Koh in May 2001 and is headquartered in London, the United Kingdom.

Gorilla Technology Group Inc

Gorilla Technology Group is trending following its full-year 2025 earnings, which reported record revenue exceeding $100 million and significant profitability improvements, fueling community debate over its perceived undervaluation and ambitious $7B+ AI infrastructure pipeline, while skeptics point to past execution concerns and low institutional ownership.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media & Technology Group (DJT) is trending due to the Trump administration's ongoing military strikes against Iran, which has ignited polarized community discussions. While proponents hail the actions as vital for global security, critics widely dismiss it as an "illegal war" and a distraction from domestic issues and the "Epstein files," fueling intense debate and contributing to the stock's volatility.

AST Spacemobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an extensive IP and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

AST SpaceMobile is trending following a positive earnings call that included accelerating satellite deployment plans, optimistic revenue growth guidance, and new partnerships with global telecom providers. The community is actively discussing the company's full funding for its constellation, expected additional announcements, and its emerging role in defense and space-based AI, prompting strong bullish sentiment against persistent skepticism.

AeroVironment, Inc. engages in the design, development, and production of multi-domain robotic systems and related services for government agencies and businesses. It operates through the following business segments: UnCrewed Systems, Loitering Munitions Systems, and MacCready Work. The UnCrewed Systems segment focuses primarily on small UAS products designed to operate reliably at lower altitudes in a wide range of environmental conditions. The Loitering Munitions Systems segment focuses primarily on tube-launched aircraft that deploy with the push of a button, fly at higher speeds than small UAS products, and perform either effects delivery or reconnaissance missions, and related support services including training, spare parts, product repair, and product replacement. The MacCready Works segment focuses on customer-funded research and development in the areas of HAPS, robotics, sensors, software analytics, data intelligence, and connectivity. The company was founded by Paul B. MacCready, Jr. in July 1971 and is headquartered in Arlington, VA.

AeroVironment Inc.

AeroVironment is experiencing extreme volatility after a downgrade tied to a significant Space Force contract being recompeted, yet many in the community are calling it an overreaction and a buying opportunity amid strong defense sector tailwinds and conflicting analyst opinions ahead of upcoming earnings.

Ouster, Inc. engages in the provision of high resolution digital lidar sensors that offer advanced 3D vision to machinery, vehicles, robots, and fixed infrastructure assets. The company was founded by Angus Pacala and Mark Frichtl on June 30, 2015 and is headquartered in San Francisco, CA.

Ouster Inc - Ordinary Shares - Class A

Strong Q4 earnings propelled Ouster to GAAP profitability with robust revenue growth and impressive gross margins, while its strategic acquisition of StereoLabs, an EBITDA-positive AI vision company, is generating significant community excitement. This move is seen as solidifying Ouster's position as a leading unified sensing and perception platform for the expanding Physical AI market across industrial, robotics, and smart infrastructure sectors.

Credo Technology Group Holding Ltd. engages in the development of connectivity solutions and products for the data infrastructure market. Its products include integrated circuits, active electrical cables, and SerDes chiplets. The company was founded by Chi Fung Cheng and Yat Tung Lam on 2008 and is headquartered in George Town, Cayman Islands.

Credo Technology Group Holding Ltd

Credo Technology Group is trending after delivering Q3 earnings that significantly beat estimates, driven by robust demand for its high-speed AI data center connectivity solutions. While the market initially reacted to conservative Q4 sales guidance, many in the community are accumulating shares, expecting Credo to continue benefiting from massive hyperscaler infrastructure spending.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

MIRA Pharmaceuticals (NASDAQ:MIRA) Stock Price Down 6.6% - Time to Sell?

MIRA Pharmaceuticals (NASDAQ:MIRA) Stock Price Down 6.6% - What's Next...

MIRA Pharmaceuticals (NASDAQ:MIRA) Shares Down 6.6% - Time to Sell?

MIRA Pharmaceuticals (NASDAQ:MIRA) Trading Down 6.6% - Time to Sell...

MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) Sees Significant Growth in Short Interest

MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA - Get Free Report) was the recipient of a large increase in short interest in the month of December. As of December 31st, there was short interest totaling...

MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) Short Interest Update

MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA - Get Free Report) was the target of a large decrease in short interest in the month of December. As of December 15th, there was short interest totaling...

MIRA Pharmaceuticals (NASDAQ:MIRA) Rating Lowered to Sell at Wall Street Zen

Wall Street Zen downgraded shares of MIRA Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Saturday...

Shares of Mira Pharmaceuticals surged 70% after-hours on Wednesday after the company announced new preclinical data showing its oral drug candidate Mira-55 outperformed injected morphine in normalizing pain and reducing inflammation in an animal model of chronic inflammatory pain.The study, conducted as part of Mira’s Mira-55 program, found that the orally administered compound not only restored pain thresholds to baseline levels but also demonstrated strong anti-inflammatory effects, pointing to a dual action that morphine failed to match.&nbsp;The company said these findings will support its planned Investigational New Drug (IND) application for chronic inflammatory pain and reinforce its position in the $70 billion non-opioid pain market.Mira-55, a non-psychotropic marijuana analog, achieved full pain normalization and significantly reduced paw swelling, confirming a CB2 receptor-mediated anti-inflammatory mechanism. Morphine, by contrast, showed only partial inflammation reduction through indirect effects on the central nervous system.The company noted that this is the first study in the program to measure inflammation directly alongside pain. The oral efficacy of Mira-55 also offers clinical convenience compared with morphine, which requires injection to achieve similar pain control.On Stocktwits, retail sentiment for Mira was ‘extremely bullish’ amid a 7,000% surge in 24-hour message volume.One user on Stocktwits called it “absolutely insane” that a small biotech like Mira could claim Mira-55 outperforms morphine, saying it could draw major investors and even qualify for FDA fast-track review. The user highlighted that Mira-55’s oral delivery and CB2 receptor action were unheard of, adding that the $60 billion+ market gives the stock huge upside potential.&nbsp;<stembedurl>https://stocktwits.com/Moobumples/message/632515002</stembedurl>Another user said he sees potential in Mira-55 becoming a “blockbuster drug” and urged others to buy.<stembedurl>https://stocktwits.com/Intradaytrade100/message/632498480</stembedurl><a href="https://stocktwits.com/symbol/MIRA">Mira Pharmaceuticals’ stock</a> has risen 16% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Mira Pharmaceuticals’ stock (MIRA) has risen 16% so far in 2025. (Photo credit: Getty Images)

Mira Pharmaceuticals Stock Soars 70% After-Hours As Pain Drug Outperforms Morphine; Retail Sees ‘Blockbuster Drug’ In The Making

The company said its oral treatment fully normalized pain and sharply reduced inflammation in preclinical studies, outperforming injected morphine. 

Equity

MIRA Pharmaceuticals Inc saw its shares rise to the highest levels in nearly two months after the clinical-stage pharmaceutical company announced the board’s approval of its planned acquisition of SKNY Pharmaceuticals Inc, a deal valued at over $60 million.The acquisition, which still requires approval from MIRA and SKNY’s shareholders, has been valued based on third-party analysis conducted by Moore Financial Consulting.&nbsp;SKNY Pharmaceuticals has an enterprise value of approximately $30.5 million, while MIRA's value stands at $30 million, bringing the combined enterprise value to over $60 million.Shares of MIRA Pharmaceuticals have gained 8.7% year-to-date, closing at $1.25 on Thursday, before dipping 6.4% in after-hours trading.MIRA CEO Erez Aminov emphasized that the merger combines two robust pipelines and a unified strategy, with a focus on developing therapies for obesity and nicotine dependence.&nbsp;Under the terms of the merger, SKNY is required to hold at least $5 million in cash or other assets to be transferred at closing.&nbsp;MIRA is preparing to file with the U.S. Securities and Exchange Commission to seek shareholder approval for the deal.SKNY Pharmaceuticals’ lead compound, SKNY-1, is being developed as a next-generation oral therapeutic targeting CB1 and CB2 cannabinoid receptors, as well as monoamine oxidase B (MAO-B), which plays a key role in dopamine metabolism and addiction regulation.&nbsp;The compound is being evaluated for its potential to address both metabolic dysfunction and nicotine dependence, with applications in two high-value therapeutic areas.MIRA’s leadership views the addition of SKNY-1 to its pipeline as a key step in positioning the company to capitalize on these growing markets. Dr. Itzchak Angel, MIRA’s Chief Scientific Advisor, Itzchak Angel, said the pharmacological profile of SKNY-1 could make it an effective treatment for both addiction and metabolic disorders.&nbsp;Early data from the compound’s development has been promising, according to Angel.On Stocktwits, sentiment was described as 'bullish' amid a 1,350% surge in 24-hour message volume.&nbsp;One user noted that the merger would be a significant win, expressing confidence that shareholders from both companies would approve, while another shared frustration over a pre-market entry at $1.70, followed by an immediate pullback.<stembedurl>https://stocktwits.com/BearTamerTrading/message/613998754</stembedurl><stembedurl>https://stocktwits.com/Kc24mo/message/613981879</stembedurl>The stock has risen 8.7% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

MIRA Pharma Stock Soars To 2-Month High On $60M SKNY Deal: Retail Sentiment Strong

Retail sentiment on Stocktwits surged, with users expressing optimism about the merger’s success, despite a pullback in after-hours trading.

Shares of Mira Pharmaceuticals&nbsp;gained over 19% on Wednesday, marking their best session in over a month, after the company's oral ketamine analog showed promising data in a preclinical study.Mira said its Ketamir-2 therapy significantly reduced pain symptoms in rats, with some test animals returning to pre-diabetic sensitivity levels.The drug outperformed standard treatments like pregabalin and gabapentin in prior studies and has shown a favorable safety profile without ketamine's psychedelic effects, the company added.On Stocktwits, the news sent 24-hour message volume involving Mira soaring 8,500% by late Wednesday — the highest among all healthcare stocks — with sentiment turning even more 'extremely bullish.'<figure class="image"><img style="aspect-ratio:1318/316;" src="https://news.stocktwits-cdn.com/MIRA_sentiment_and_message_volume_as_of_April_16_png_9320cb3838.webp" alt="MIRA sentiment and message volume as of April 16.png" width="1318" height="316"><figcaption>MIRA sentiment and message volume as of April 16. | source: Stocktwits</figcaption></figure>One watcher expects the stock to cross the $1.2 mark on Thursday easily.<stembedurl>https://stocktwits.com/BadBritt/message/611883890</stembedurl>Another said a new 52-week high was imminent.<stembedurl>https://stocktwits.com/HMIC/message/611835137</stembedurl>Mira has already begun dosing and testing Ketamir-2 in a Phase I trial in Israel, which is expected to be completed in the fourth quarter of 2025.&nbsp;A Phase IIa trial in diabetic neuropathy is set to begin by the end of 2025, with efficacy data anticipated in early 2026.&nbsp;Mira is also developing a topical formulation for localized pain and exploring Ketamir-2's potential in PTSD treatment.Separately, Mira is progressing with its acquisition of SKNY Pharmaceuticals and sees promise in SKNY-1, a next-generation oral therapy targeting obesity and smoking cessation.Mira Pharmaceuticals' stock has lost over 8% this year but has risen nearly 29% over the past 12 months.Shares of the company fell over 11% after-hours on Wednesday, likely due to profit-taking.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Mira Pharma Leads Healthcare Buzz Surge On Promising Oral Ketamine Analog Preclinical Trial

The drug outperformed standard treatments like pregabalin and gabapentin in prior studies and has shown a favorable safety profile without ketamine's psychedelic effects. 

Small-cap biotech Mira Pharmaceuticals (MIRA) has experienced a meteoric rise and subsequent plunge, captivating retail investors in the process.The company's stock surged a staggering 627% on Monday following promising preclinical data for its novel oral ketamine analog, Ketamir-2. This dramatic increase sparked a frenzy of interest, with the number of Stocktwits followers surging over 212% in just one week.Ketamir-2 has shown potential as a treatment for neurological and neuropsychiatric disorders, according to media <a href="https://www.benzinga.com/news/24/07/39885749/nano-cap-mira-pharmaceuticals-oral-ketamine-analog-shows-potential-in-neuropsychiatric-disorders?utm_source=TechInvestorNews&amp;utm_campaign=partner_feed&amp;utm_medium=partner_feed&amp;utm_content=site">reports</a>. Unlike traditional ketamine, it exhibits better oral bioavailability and appears to have a reduced risk of side effects. These advantages could position Mira as a significant player in the development of novel therapies.The company is also preparing to submit an Investigational New Drug (IND) application to the FDA by the end of this year.However, the euphoria was short-lived. The stock plummeted over 54% on Tuesday, prompting some to take profits while they still had them.Although some investors believe this represents a buying opportunity, others remain cautious, citing the long road to commercialization and the potential for future volatility.The Stocktwits stream had plenty of bearish posts, like the one from “<a href="https://stocktwits.com/Wolf_Of_Penny_Stocks/message/580409064">Wolf_of_penny_stocks</a>”, advising investors to “scalp and run” as Monday’s stock move was a “pump on preclinical data… even if they are successful it will take another 8-10 years before they generate any revenue.”<figure class="image"><img style="aspect-ratio:1320/450;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Stocktwits_user_comment_on_MIRA_stream_Jul_23_1a46479621.png" alt="Stocktwits user comment on MIRA stream Jul 23.png" width="1320" height="450"><figcaption>Stocktwits user comment on MIRA stream Jul 23</figcaption></figure>The rapid rise and fall of Mira Pharmaceuticals highlights the speculative nature of the biotech sector. While preclinical data is undoubtedly encouraging, investors must approach such volatile stocks with caution and conduct thorough due diligence before making investment decisions, as many posts on MIRA’s Stocktwits stream suggest. &nbsp;

Why Small-Cap Mira Pharma's Retail Following Has Tripled From Last Week

The tiny company's Mira Pharma stock price and Stocktwits following exploded after promising preclinical data for its novel drug, Ketamir-2.

Mira Pharma's Retail Following Has Tripled From Last Week

The tiny company's stock price and Stocktwits following exploded after promising preclinical data for its novel drug, Ketamir-2. However, a subsequent freefall has left investors wondering if this was a flash in the pan or the start of something bigger.

MIRA Pharmaceuticals, Inc. operates as a clinical development stage biopharmaceutical company. It engages in developing its product candidates, Ketamir-2 and MIRA-55, designed to address unmet medical needs in pain management, depression, PTSD, and cognitive function. The company was founded by Adam Kaplin on September 3, 2020 and is headquartered in Miami, FL.

Mira Pharmaceuticals Inc

Beat EPS and revenue

Beat EPS, miss revenue

Miss EPS, beat revenue

Miss EPS and revenue

What do you expect from $MDB earnings today?

Current Price	$1.29
Prev Close	$1.27
Open	$1.22
Dividend Yield	0.00%
50-Day Moving Average	$1.37
Beta	0.00
Avg. Volume	153,176.50
PE Ratio	-0.83

52-Week High	$2.45
52-Week Low	$0.73
Market Capitalization	$53.18M
EPS (Annual)	-$0.5085
Price to Book	6.65
Revenue Per Employee	$0.00

MIRA
Mira Pharmaceuticals Inc

Feed

News

Sentiment

Fundamentals

Info

Latest MIRA News

MIRAMira Pharmaceuticals Inc